IN THE UNITED STATES PATENT AND TRADEMARK OFFICE M

ANDERSON, DARRELL R., et al.

al New 07/978,891

Group Art Unit: 1805 18 5

iled: 13 November 199

Examiner: Schwadron, R.

Title:

THERAPEUTIC APPLICATION OF CHIMERIC ANTIBODY TO HUMAN B

LYMPHOCYTE RESTRICTED

DIFFERENTIATION ANTIGEN FOR

TREATMENT OF B CELL

LYMPHOMA

RECEIVED

MAY 1 9 1993 GROUP 1800

May 10, 1993 La Jolla, CA

RESPONSE TO EXAMINER COMMUNICATION DATED APRIL 8, 1993

Hon. Commissioner of Patents and Trademarks BOX NON-FEE AMENDMENT Washington, D.C. 20231 RECEIVED
MAY 1 9 1993
GROUP 1800

Sir:

On April 19, 1993, the Office notified Applicants of a bona fide, but incomplete, response to the January 11, 1993 Notice to Comply. Applicants regret any inconvenience caused by the inadvertence.

The Office has noted certain errors in the submitted Sequence Listing, and has requested:

- 1. A substitute Computer Readable Form ("CRF") copy of the Sequence Listing;
- 2. A paper copy of the Sequence Listing with an amendment directing its entry into the Specification; and
- 3. A Rule 821 Statement.

Attached hereto please find: (1) a substitute CRF; a paper copy of the CRF; a Preliminary Amendment directing its entry into the Specification; and a Rule 821 Statement.

Applicants request that the foregoing be entered and that examination-on-themerits for this case be initiated.

Respectfully submitted,

Richard P. Burgoon, Jr.
Intellectual Property Counsel

Reg. No. 34,787

IDEC Pharmaceuticals Corporation

11099 N. Torrey Pines Road, #160

La Jolla, CA 92037